Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Visualitza/Obre
Autor/a
Pradenas, Edwards
Trinité, Benjamin
Urrea, Víctor
Marfil, Silvia
Ávila-Nieto, Carlos
Rodríguez de la Concepción, María Luisa
Tarrés-Freixas, Ferran
Pérez-Yanes, Silvia
Rovirosa, Carla
Ainsua-Enrich, Erola
Rodon, Jordi
Vergara-Alert, Júlia
Guallar, Victor
Valencia, Alfonso
Izquierdo-Useros, Nuria
Paredes, Roger
Mateu, Lourdes
Chamorro, Anna
Massanella, Marta
Carrillo, Jorge
Clotet, Bonaventura
Blanco, Julià
Data de publicació
2021-01-31ISSN
2666-6340
Resum
Background. Understanding mid-term kinetics of immunity to SARS-CoV-2 is the cornerstone for public health control of the pandemic and vaccine development. However, current evidence is rather based on limited measurements, losing sight of the temporal pattern of these changes. Methods. We conducted a longitudinal analysis on a prospective cohort of COVID-19 patients followed up for >6 months. Neutralizing activity was evaluated using HIV reporter pseudoviruses expressing SARS-CoV-2 S protein. IgG antibody titer was evaluated by ELISA against the S2 subunit, the receptor binding domain (RBD), and the nucleoprotein (NP). Statistical analyses were carried out using mixed-effects models. Findings. We found that individuals with mild or asymptomatic infection experienced an insignificant decay in neutralizing activity, which persisted 6 months after symptom onset or diagnosis. Hospitalized individuals showed higher neutralizing titers, which decreased following a 2-phase pattern, with an initial rapid decline that significantly slowed after day 80. Despite this initial decay, neutralizing activity at 6 months remained higher among hospitalized individuals compared to mild symptomatic. The slow decline in neutralizing activity at mid-term contrasted with the steep slope of anti-RBD, S2, or NP antibody titers, all of them showing a constant decline over the follow-up period. Conclusions. Our results reinforce the hypothesis that the quality of the neutralizing immune response against SARS-CoV-2 evolves over the post-convalescent stage.
Tipus de document
Article
Versió del document
Versió acceptada
Llengua
English
Matèries (CDU)
619 - Veterinària
Pàgines
24
Publicat per
Elsevier
Publicat a
Med
Citació
Pradenas, Edwards, Benjamin Trinité, Víctor Urrea, Silvia Marfil, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, and Ferran Tarrés-Freixas et al. 2021. "Stable Neutralizing Antibody Levels 6 Months After Mild And Severe COVID-19 Episodes". Med 2 (3): 313-320.e4. doi:10.1016/j.medj.2021.01.005.
Programa
Sanitat Animal
Aquest element apareix en la col·lecció o col·leccions següent(s)
- ARTICLES CIENTÍFICS [2831]
Excepte que s'indiqui una altra cosa, la llicència de l'ítem es descriu com http://creativecommons.org/licenses/by-nc-nd/4.0/